曲美他嗪对急诊冠状动脉介入术后造影剂肾病的保护作用

PROTECTIVE EFFECT OF TRMIETAZIDINE ON CONTRAST-INDUCED NEPHROPATHY IN ACUTE CORONARY INTERVENTION

目的探讨曲美他嗪在预防急性心肌梗死患者行急诊冠状动脉介入(PCI)术后造影剂肾病(CIN)的作用。方法将2009—2011年住院行急诊PCI术治疗的急性心肌梗死患者100例随机分为曲美他嗪组和对照组,分别测定并比较二组患者造影后24、72h的血清尿素氮(BUN)、血清肌酐(Scr)、内生肌酐清除率(Ccr)以及造影剂肾病的发生率。结果曲美他嗪组与对照组基础状态包括年龄、性别、糖尿病史、高血压病史、吸烟史、体重指数、左室射血分数(LVEF)及用药情况等基线资料间差异无统计学意义(P>0.05)。与对照组术前Scr相比,对照组术后72h Scr水平明显升高,差异有统计学意义(P<0.05),曲美他嗪组术后72h Scr明显低于对照组术后72h Scr,差异有统计学意义(P<0.05)。结论应用曲美他嗪可能对患者急诊PCI术后CIN的发生具有一定的预防保护作用。

Objective To study the prevention effect of Trmietazidine on contrast -induced nephropathy in ST - segment elevation myocardial infarction undergoing primary percutaneous coronary intervention . Methods A total of 100 consecutive patients with ST -segment elevation myocardial infarction admitted to a single invasive heart center and treated with primary percutaneous coronary intervention from January 2009 to January 2011 were included .The patients were divided into Trmietazidine group and control group . Results At baseline ,there were no statistically significant difference in age ,sex ,diabetes history ,hyper-tension history ,smoke history ,body mass index （BMI） ,LVEF and remedy was found between the two groups （P〉0 .05） .However ,there was statistically significant higher in 72 hours after PPCI than admis-sion in control group（P〈0 .05） .There was statistically significant lower in 72 hours after PPCI in the Trmietazidine group than 72 hours after PPCI in control group（P〈0 .05） .Conclusion Using Trmietazi-dine on admission may improve the morbidity of CIN in STEMI patients undergoing primary PCI .